Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Ross Moat sold 27,977 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $92.36, for a total transaction of $2,583,955.72. Following the completion of the sale, the chief operating officer owned 10,294 shares in the company, valued at approximately $950,753.84. This represents a 73.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ross Moat also recently made the following trade(s):
- On Friday, October 30th, Ross Moat sold 75,608 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $93.13, for a total transaction of $7,041,373.04.
Kiniksa Pharmaceuticals International Stock Up 2.7%
NASDAQ KNSA traded up $2.49 on Tuesday, hitting $93.29. The stock had a trading volume of 1,021,631 shares, compared to its average volume of 705,858. Kiniksa Pharmaceuticals International, plc has a one year low of $37.02 and a one year high of $98.48. The stock has a market cap of $7.28 billion, a price-to-earnings ratio of 71.76 and a beta of 0.04. The company's 50-day moving average is $79.39 and its two-hundred day moving average is $60.29.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating analysts' consensus estimates of $0.37 by $0.19. The company had revenue of $285.97 million for the quarter, compared to analysts' expectations of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.26 earnings per share for the current year.
Wall Street Analyst Weigh In
KNSA has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 12th. Citigroup boosted their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Canaccord Genuity Group upped their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Wells Fargo & Company increased their price objective on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, October 28th. Finally, The Goldman Sachs Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a "buy" rating in a research note on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $100.57.
View Our Latest Report on Kiniksa Pharmaceuticals International
Institutional Investors Weigh In On Kiniksa Pharmaceuticals International
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Ethic Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $726,000. Pictet Asset Management Holding SA raised its holdings in shares of Kiniksa Pharmaceuticals International by 41.3% in the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company's stock worth $64,182,000 after purchasing an additional 251,578 shares in the last quarter. AlphaCentric Advisors LLC acquired a new stake in Kiniksa Pharmaceuticals International during the third quarter valued at approximately $596,000. Commonwealth Equity Services LLC lifted its stake in Kiniksa Pharmaceuticals International by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company's stock valued at $811,000 after purchasing an additional 237 shares during the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new stake in Kiniksa Pharmaceuticals International during the third quarter valued at approximately $226,000. 53.95% of the stock is owned by institutional investors and hedge funds.
Kiniksa Pharmaceuticals International Company Profile
(
Get Free Report)
Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.
Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.
The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.
While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.